FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia

23 Oct 2026 0 comments

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Source: NeurologyLive Published 22 Oct 2026 Imported 22 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment